We noticed that methylation of specific CpG sites cg18181703 (SOCS3), cg11024682 (SREBF1), and cg19693031 (TXNIP) in blood DNA was not associated with future T2DM risk in the Botnia prospective study of 148 1:1 nested case-control pairs for incident T2DM in Finland, including 11 male and 8 female monozygotic twin pairs discordant for T2DM, as described in the abstract of the paper [43]. The gene discussed is SREBF1; the disease is type 2 diabetes mellitus.